A small study - released in the past week - entitled Near-infrared (NIR) perfusion angiography in minimally invasive colorectal surgery, used Novadaq's PINPOINT in surgery on 30 consecutive patients. The mantra continues - no leaks. Go PILLAR.
Exactly - the evidence keeps piling up - it is somewhat surprising that this technology has not become the "standard of care" in certain indications by now. Ultimately, it will and this will be a $100 stock, but it gets frustrating sometimes how slow the adoption rate is?
Not sure if you saw the investor day presentation, but one of the presenter doctors indicated that if the results
of the second half of the pilar study are as good as the first half, the medical industry will be confronted with a moral dilemna. Should they immediately move to making Pinpoint a standard of care or require a confirmatory phase III study that will take a great deal of time to accomplish. This latest 30 patient study adds fuel to the fire.